AstraZeneca’s Imfinzi Sales Climb 28% to $6.06B in 2025
AstraZeneca’s Imfinzi generated $6.06 billion in 2025 sales, a 28% year-over-year increase driven by expanded bladder and liver cancer indications. This strong performance cements Imfinzi’s role as a critical growth driver as PD-1/PD-L1 competition from Merck’s Keytruda and Roche’s Tecentriq intensifies.
1. Imfinzi 2025 Performance
Imfinzi recorded $6.06 billion in 2025 sales, marking a 28% year-over-year increase driven by strong uptake in bladder and liver cancer treatment.
2. Label and Indication Expansion
During 2025, AstraZeneca secured expanded approvals for Imfinzi in additional bladder and liver cancer settings, broadening its clinical utility and patient reach.
3. Competitive Landscape
Imfinzi competes directly with Merck’s Keytruda and Roche’s Tecentriq in the PD-1/PD-L1 segment, leveraging its growing label portfolio to counter rivals and prepare for future shifts.
4. Strategic Growth Initiatives
AstraZeneca is bolstering Imfinzi through ongoing clinical trials and targeted geographic rollouts to sustain momentum and solidify its immuno-oncology leadership.